We are dedicated to bringing products which significantly improve patient lives in the world of dermatology.

Delivering innovation in acne treatment

We’re bringing our commitment to quality, value and support for prescribers and patients to the dermatology space. With WINLEVI®▼ (clascosterone), our first-in-class topical treatment for acne vulgaris – an innovation which has set new standards of care in dermatology – we are laying the foundations of excellence that define all Glenmark products.

Delivering for patients and the health system

Acne contributes to significant burden, both for patients who have to live with a challenging chronic skin condition, and for the health service as HCPs struggle to prescribe a treatment that can deliver results for a wide range of patients.¹ Working with the dermatology community, Glenmark is determined to make a difference for these patients, and help ease the burden on prescribers and payers.

Delivering excellence together!

WINLEVI (clascoterone) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.²
WINLEVI UK prescribing information

Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Glenmark Pharmaceuticals Europe Ltd medical_information@glenmarkpharma.com or call 0800 458 0383

References: 1. Layton AM, et al. Br J Dermatol. 2021;184(2):219-225. 2. WINLEVI Summary of Product Characteristics.